Leading-edge products add to their appeal back units

Article Excerpt

We think the healthcare industry will enjoy great success over the next decade. But due to the nature of the business, results will vary widely and unpredictably from one company to another. A volatile market like the one we expect for healthcare stocks will include winners and losers. Here are two that we expect to be among the big winners. BOSTON SCIENTIFIC CORP., $53.72, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $77.2 billion; No dividends paid) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty (blood vessel repair), blood clot filtration, cardiac rhythm management, catheter-aided ultrasound imaging, and many other surgical procedures. It generates 60% of its sales in the U.S. and 40% internationally. In the three months ended March 31, 2023, Boston Scientific’s revenue rose 12.0%, to $3.39 billion from $3.03 billion a year earlier. Excluding one-time items, the company earned $673.0 million, or $0.47…